Adami S, Bertoldo F, Brandi M L, Cepollaro C, Filipponi P, Fiore E, Frediani B, Giannini S, Gonnelli S, Isaia G C, Luisetto G, Mannarino E, Marcocci C, Masi L, Mereu C, Migliaccio S, Minisola S, Nuti R, Rini G, Rossini M, Varenna M, Ventura L, Bianchi G
Membri del Consiglio Direttivo SIOMMMS.
Reumatismo. 2009 Oct-Dec;61(4):260-84. doi: 10.4081/reumatismo.2009.260.
The guidelines for the osteoporosis management were first drafted by a working group and then critically evaluated by the board of SIOMMMS. The most relevant points are:
Osteoporosis is defined as a quantitative and qualitative deterioration of bone tissue leading to increased risk of fracture. Postmenopausal and senile osteoporosis are defined as primitive.
The cornerstone for the diagnosis of osteoporosis is the measurement of bone mineral density (BMD) by DXA (dual-energy X-ray absortiometry) at the femoral neck with T-score values <-2.5, following the WHO definition. Other DXA sites or technologies for measuring bone mass are also acceptable when the former is not accessible. A BMD evaluation is recommended to all women above 65 years of age. At younger age or in man the bone assessment is recommended only in subjects with specific risk factors. A control of bone mass measurement is seldom required before 2 years.
A few biochemical tests such as serum and urinary calcium, protein electrophoresis, serum creatinine and ESR are usually sufficient to exclude most secondary types of osteoporosis. The value of the so called bone turnover markers for the diagnosis and follow-up of osteoporosis remains uncertain. Several secondary forms of osteoporosis require a specific diagnostic and therapeutic management.
The osteoporosis prevention should be based on the elimination of specific risk factors such as inadequate calcium and vitamin D intake, smoking and sedentary life. The use of pharmacological agents in subjects with BMD values >-2.5 is usually not justified. Pharmacological intervention: The use of drugs registered for the treatment of osteoporosis are recommended when the benefits overcome the risk. This is the case only when the risk of fracture is rather high. FRAX is recognized as a useful tool for easily estimate the long-term fracture risk. SIOMMMS with these guidelines is committed to validate and further develop this diagnostic tool.
骨质疏松症管理指南首先由一个工作组起草,然后由意大利骨矿物质代谢与骨骼疾病学会(SIOMMMS)董事会进行严格评估。最相关的要点如下:
骨质疏松症被定义为骨组织在数量和质量上的恶化,导致骨折风险增加。绝经后骨质疏松症和老年性骨质疏松症被定义为原发性骨质疏松症。
根据世界卫生组织的定义,骨质疏松症诊断的基石是通过双能X线吸收法(DXA)测量股骨颈的骨密度(BMD),T值<-2.5。当无法进行股骨颈测量时,其他DXA测量部位或测量骨量的技术也是可以接受的。建议对所有65岁以上的女性进行骨密度评估。在较年轻的年龄段或男性中,仅建议对有特定风险因素的受试者进行骨评估。在2年内很少需要进行骨量测量的对照。
一些生化检查,如血清和尿钙、蛋白电泳、血清肌酐和红细胞沉降率,通常足以排除大多数继发性骨质疏松症类型。所谓的骨转换标志物在骨质疏松症诊断和随访中的价值仍不确定。几种继发性骨质疏松症形式需要特定的诊断和治疗管理。
骨质疏松症的预防应基于消除特定风险因素,如钙和维生素D摄入不足、吸烟和久坐不动的生活方式。对于骨密度值>-2.5的受试者,通常没有理由使用药物制剂。
当益处大于风险时,建议使用已注册用于治疗骨质疏松症的药物。仅在骨折风险相当高的情况下才是如此。FRAX被认为是一种有助于轻松估计长期骨折风险的有用工具。SIOMMMS通过这些指南致力于验证并进一步开发这种诊断工具。